-
Mashup Score: 0
The U.S. Preventive Services Task Force released a draft recommendation that women aged 21 to 65 years be regularly screened for cervical cancer.According to the task force, women aged 21 to 29 years should receive a Pap test every 3 years, while women aged 30 to 65 years should receive a high-risk HPV test every 5 years or alternatively receive aPap test every 3 years and a combined high-risk
Source: www.healio.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0“A universal challenge’: Increasing lifespan dulled by nearly a decade of disease effects - 3 hour(s) ago
Global increases in life expectancy have been accompanied by a similar rise in the number of years living with the effects of disease. This difference between life expectancy and disability-free healthy living, what researchers called the healthspan-lifespan gap, has grown to almost 10 years over the last 2 decades, the results of a cross-sectional analysis of WHO member states published in JAMA
Source: www.healio.comCategories: General Medicine News, General HCPsTweet-
Among #WHO member states, global increases in life expectancy have been accompanied by a similar rise in the number of years living with the effects of disease 🌐 #health 🔗: https://t.co/OY182q5f8i
-
-
Mashup Score: 2Delayed methotrexate start improves pneumococcal vaccine response in rheumatoid arthritis - 3 hour(s) ago
WASHINGTON — Delaying methotrexate initiation for 1 month after pneumococcal vaccination improves humoral response in patients with rheumatoid arthritis, according to data presented at ACR Convergence 2024. “As you know, vaccination against pneumococcus is recommended in patients with RA being treated with methotrexate,” Jacques Morel, MD, of the University Hospital of
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🗨️“This is the first study to show it is better to vaccinate RA patients with PCV13 1 month before #methotrexate initiation with no impact on RA disease activity” More from Dr. Jacques Morel @CHU_Montpellier at #ACR24 ⬇️ https://t.co/gAU1Sf0ol9
-
-
Mashup Score: 0
SAN ANTONIO — The addition of pyrotinib to first-line trastuzumab and docetaxel improved PFS among patients with HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.The combination also exhibited a manageable safety profile.
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
The addition of pyrotinib to first-line trastuzumab and docetaxel improved PFS among patients with HER2-positive metastatic breast cancer, according to data presented at #SABCS24. #BreastCancer @SABCSSanAntonio https://t.co/49HXEZIn8x
-
-
Mashup Score: 0Anthem retracts ‘morally abhorrent’ policy to put time limit on anesthesia during surgery - 4 hour(s) ago
Following backlash, Anthem Blue Cross Blue Shield stalled its policy change that would have put a time limit on coverage for anesthesiology services during surgery and other procedures in Connecticut, Missouri and New York.The proposed policy update, set to be effective Feb. 1, 2025, would have allowed Anthem to determine the allowed allotted time for anesthesia during a surgery and would only
Source: www.healio.comCategories: General Medicine News, GastroenterologyTweet-
Following backlash, @AnthemBCBS stalled 🛑 its policy change that would have put a time limit⌚ on coverage for #anesthesiology services during surgery and other procedures in: 👉🏻Connecticut, 👉🏻Missouri 👉🏻New York Learn more 🔽🔽 https://t.co/5C5XaGw7lM
-
-
Mashup Score: 0Olaparib confers durable benefit in BRCA -mutated breast cancer - 4 hour(s) ago
SAN ANTONIO — One year of adjuvant olaparib after standard treatment improved outcomes compared with placebo among patients with high-risk BRCA-mutated breast cancer, according to data presented at San Antonio Breast Cancer Symposium.Results of the third prespecified interim analysis of the randomized OlympiA trial showed a durable benefit in invasive DFS — the study’s primary
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
One year of adjuvant olaparib after standard treatment improved outcomes compared with placebo among patients with high-risk BRCA-mutated breast cancer, according to data presented at #SABCS24. #Lynparza #BreastCancer https://t.co/qlsYapoOqD
-
-
Mashup Score: 1
SAN ANTONIO — Imlunestrant alone or as part of combination therapy extended PFS for certain patients with advanced breast cancer resistant to hormone therapy, according to study results presented at San Antonio Breast Cancer Symposium.The randomized phase 3 EMBER-3 trial included patients with ER-positive, HER2-negative advanced disease who had received endocrine therapy alone or with a
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
Imlunestrant alone or as part of combination therapy extended PFS for certain patients with advanced breast cancer resistant to hormone therapy, according to data presented at #SABCS24. #BreastCancer @SABCSSanAntonio https://t.co/mQvucQuiPn
-
-
Mashup Score: 0Risk-reducing surgeries extend survival among young BRCA carriers with breast cancer history - 5 hour(s) ago
SAN ANTONIO — Risk-reducing surgery appeared linked with improved outcomes among BRCA mutation carriers diagnosed with early breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.Those who underwent bilateral risk-reducing mastectomy and/or risk-reducing salpingo-oophorectomy exhibited reduced risk for recurrence, lower incidence of secondary breast
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
Risk-reducing surgery appeared linked to improved outcomes among BRCA mutation carriers diagnosed with early breast cancer, according to data presented at #SABCS24. Healio spoke with @matteolambe of @UniGenova and @SanMartino_Ge about the data. https://t.co/xkOc2uKvot
-
-
Mashup Score: 0Breast cancer researcher receives lecture award at SABCS - 5 hour(s) ago
Laura J. van ’t Veer, PhD, will receive the William L. McGuire Memorial Lecture Award at this year’s San Antonio Breast Cancer Symposium, scheduled for Dec. 10-13.The award recognizes van ’t Veer for her work advancing risk stratification, subtyping and improved treatment for early breast cancer.
Source: www.healio.comCategories: General Medicine News, Oncologists1Tweet-
The winner of this year's William L. McGuire Memorial Lecture Award at #SABCS24 is @LVVPrint. The award recognizes van ’t Veer for her work advancing risk stratification, subtyping and improved treatment for early breast cancer. #BreastCancer https://t.co/2HeufTsZFK
-
-
Mashup Score: 1Early weight loss with tirzepatide predictive of larger cardiometabolic benefits later on - 7 hour(s) ago
SAN ANTONIO — Tirzepatide confers significant weight loss and cardiometabolic benefits for patients with diabetes and overweight or obesity, especially for those who lose more weight earlier during treatment, a speaker reported.At ObesityWeek, Tina K. Thethi, MD, MPH, associate investigator at the AdventHealth Translational Research Institute and endocrinologist at the AdventHealth Diabetes
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
📢 The #weightloss and cardiometabolic benefits of #tirzepatide at 72 weeks were greater among early responders to treatment (5% or more weight loss at 8 weeks) @ObesityWeek @ObesitySociety @GoHealio @CardiologyToday Read more ⬇️ https://t.co/DFL0P9nler
-
#ED visits resulting from electronic bicycle and scooter injuries rose threefold from 2019 to 2022, new data show 🛵 #Alcohol and substance use particularly increased the odds for these types of visits 🍺 Read more: https://t.co/Su9axYWEkU